|
Evaluating Impurities in Drugs (Part III of III)
April 2, 2012
By:
Kashyap R. Wadekar
,
Ponnaiah Ravi
,
Mitali Bhalme
,
S. Srinivasa Rao
,
K. Vigneshwar Reddy
,
L. Sampath Kumar
,
E. Balasubrahmanyam
In Part III of a three-part article, the authors examine various degradation routes of APIs, impurities arising from interactions in formulations, metabolite impurities, various analytical methods to measure impuritie, and ways to control impurities.
|
|
Evaluating Impurities in Drugs (Part II of III)
March 2, 2012
By:
Kashyap R. Wadekar
,
Mitali Bhalme
,
S. Srinivasa Rao
,
K. Vigneshwar Reddy
,
L. Sampath Kumar
,
E. Balasubrahmanyam
In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.
|
|
Evaluating Impurities in Drugs (Part I of III)
February 2, 2012
By:
Kashyap R. Wadekar
,
Mitali Bhalme
,
S. Srinivasa Rao
,
K. Vigneshwar Reddy
,
L. Sampath Kumar
,
E. Balasubrahmanyam
In Part I of a three-part article, the authors discuss what constitutes an impurity and the potential sources of impurities in APIs and finished drug products.
|
|
